samedan logo
 
 
spacer
home > pmps > winter 2002 > starch based excipients for tabletting
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Starch Based Excipients for Tabletting

Excipients are commonly defined as the additives used to convert pharmacologically active compounds into a pharmaceutical dosage form suitable for administering to patients. They are useful both as diluent of the active drug and processing aid for the formulation. Excipients should be physiologically inert and compatible with active ingredients. They should show no ageing in terms of physical and chemical stability and should be neutral in terms of odour, taste and colour. Many natural carbohydrates and their derivatives meet these requirements and therefore are widely used in the pharmaceutical industry.

Wet and dry granulation are frequently used methods for the manufacturing of tablets. But with the availability of specific developed excipients the pharmaceutical industry has the opportunity to choose a more efficient and economical process: direct compression. The choice of excipient is extremely critical in formulating direct compression tablets. Longstanding suppliers of pharmaceutical excipients, are therefore proactive in the research and development of new forms of excipient that are suitable for direct compression.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr Jacques Michaud, Business Manager Pharma & Cosmetics at Cerestar, Belgium
Dr Jacques Michaud obtained a PhD in Organic Chemistry in 1990 from the Universitй Pierre et Marie Curie, Paris VI. Dr Michaud has been working for Cerestar since 1990 where he managed the Application Centre Pharma & Chemical in the R&D centre of Cerestar in Vilvoorde, Belgium. The centre is in charge of developing new applications of starch and starch derivatives for the chemical and the pharmaceutical industries.

Dr Michaud is an expert at the European Pharmacopoeia and represents his company at the IPEC. He has been recently appointed Business Manager, and is responsible for co-ordinating the technical and commercial activities of Cerestar in the pharmaceutical and cosmetics applications.

spacer
Dr Jacques Michaud
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology, Advancing Novel Medicines to Patients Using Machine Learning and High Content Screening Methods at Scale to Map Complex Biology

The deal, worth several billion dollars, is a future-looking model of technology-enabled target and drug discovery
More info >>

White Papers

Technology Solutions - Driving efficiencies, quality and operational excellence

Worldwide Clinical Trials Ltd

Clinical trials involve the entry, analysis and reporting of millions of pieces of data; year-on-year, the amount of data required to manage efficacy and safety increases exponentially. Recently, solutions available to support this activity have grown in numbers and complexity. The rise of Tablets and Smart Phones combined with the growth of Cloud or SAS solutions has resulted in the technology landscape required to support complex, global studies becoming more confusing.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement